May 4, 2017

ALEXANDRIA, Va. --  CancerLinQ LLC, a wholly-owned nonprofit of the American Society of Clinical Oncology (ASCO), has announced a partnership with the Oncology Nursing Society (ONS). CancerLinQ will draw on ONS's expertise and thought leadership as it continues to provide a robust quality improvement and data-sharing platform to oncology practices and cancer centers. The collaboration builds on the CancerLinQ® Ambassadors Program, which the two organizations launched earlier this year

May 2, 2017

ALEXANDRIA, Va. --  CancerLinQ LLC, a wholly owned nonprofit subsidiary of the American Society of Clinical Oncology (ASCO®), has announced that Santa Clara Valley Medical Center (SCVMC) in San Jose, Calif. has signed an agreement to participate in the CancerLinQ® platform. 

February 22, 2017

ALEXANDRIA, Va. – CancerLinQ LLC and the American Society for Radiation Oncology (ASTRO) are partnering to bring radiation oncology expertise to CancerLinQ® and improve the care of cancer patients nationwide. ASTRO will provide guidance for the development of the CancerLinQ® platform to ensure that the system captures more relevant patient data to drive actionable decision-making in cancer care, as well as to advance public policy and population health issues. ASTRO also will use insights from CancerLinQ Discovery™ to improve the care of patients receiving radiation therapy.

February 7, 2017

ALEXANDRIA, Va.CancerLinQ LLC, a wholly owned nonprofit subsidiary of the American Society of Clinical Oncology (ASCO®), has announced that the University of Virginia (UVA) Cancer Center has signed an agreement to participate in the CancerLinQ® platform. 

December 5, 2016

ALEXANDRIA, Va. -- CancerLinQ LLC, a wholly owned nonprofit subsidiary of the American Society of Clinical Oncology (ASCO®), has announced that George A. Komatsoulis, Ph.D., will be its first Chief of Bio-Informatics. This marks another step toward the organization's goal of making the CancerLinQ® platform the premier system for unlocking patient data from millions of electronic health records (EHR), breaking down silos among various EHR systems and providers, and securely processing and analyzing the data to give personalized insights than can improve the quality of care for patients with cancer.

November 30, 2016

Alexandria, Va. – CancerLinQ LLC, a nonprofit subsidiary of the American Society of Clinical Oncology® (ASCO), today announced CancerLinQ Discovery™, a groundbreaking offering that will provide insights through the analysis of real-world cancer care data. CancerLinQ Discovery will provide highly curated, de-identified sets of clinical data with the objective of creating new clinical knowledge and improving patient outcomes. It will derive these sets from the rapidly-growing CancerLinQ® database, which now includes over 1.5 million patient records and more than 70 oncology practices that have agreed to contribute data to CancerLinQ’s core quality improvement and data-sharing platform.

October 20, 2016

ALEXANDRIA, Va. – CancerLinQ LLC, a wholly-owned nonprofit of the American Society of Clinical Oncology (ASCO), announced today that more than one million patient records are now in the CancerLinQ™ platform. In addition, 70 practices have signed agreements to participate in CancerLinQ, representing more than 1,500 oncologists.

October 10, 2016

ALEXANDRIA, Va. – CancerLinQ LLC (CLQ LLC) CEO Kevin Fitzpatrick has been appointed to the Cancer Informatics for Cancer Centers (CI4CC) Corporate Advisory Board. CancerLinQ LLC is a wholly owned nonprofit subsidiary of the American Society of Clinical Oncology, Inc. (ASCO®) and Mr. Fitzpatrick’s appointment builds on CI4CC and CLQ LLC’s collaborative efforts to help improve cancer care.

June 27, 2016

The American Society of Clinical Oncology (ASCO) and CancerLinQ LLC will join Vice President Joe Biden and other leaders in the cancer community for the Cancer Moonshot Summit at Howard University, on June 29, to launch new collaborations and exchange ideas on solving the complexities of cancer care.

June 5, 2016

ASCO announced today that a total of 58 practices in 39 states and the District of Columbia have joined CancerLinQ™, ASCO’s big data initiative to rapidly improve the quality of care for people with cancer. CancerLinQ is already up and running in a number of practices and drawing on approximately three-quarters of a million patient records from across the United States.

June 5, 2016

CancerLinQ LLC, a wholly owned nonprofit subsidiary of the American Society of Clinical Oncology, Inc. (ASCO®), has announced a collaborative effort with the Cancer Informatics for Cancer Centers (CI4CC). This initiative will bring the nation’s leading clinical, genomics, and biomedical informaticists, academicians, applied research information technology (IT) professionals, and data scientists together with the oncology community to help improve cancer care.

April 21, 2016

ALEXANDRIA, Va. – CancerLinQ LLC announced today that it has completed agreements with 36 oncology practices from around the country to begin implementing CancerLinQ™, the groundbreaking health information technology (HIT) platform that will harness big data analytics to help oncologists rapidly improve high-quality care to patients with cancer. CancerLinQ LLC is a wholly-owned nonprofit subsidiary of the American Society of Clinical Oncology (ASCO).

February 4, 2016

Three Industry Leaders Join the CancerLinQ™ Team to Help Guide Big-Data Initiative

December 5, 2015

The Conquer Cancer Foundation of the American Society of Clinical Oncology (ASCO) has received a second $1 million from Susan G. Komen® toward the development of CancerLinQ™, a big data project that aims to rapidly improve the overall quality of cancer care. This donation builds on Komen’s previous support of this initiative.

July 22, 2015

ALEXANDRIA, Va.—Ronald A. “Ronnie” Andrews, Jr., has joined the Board of Governors of CancerLinQ LLC, a wholly owned non-profit subsidiary of the American Society of Clinical Oncology (ASCO) established for the development and operation of CancerLinQ™.  Mr. Andrews has nearly 30 years of experience in the clinical and molecular diagnostics industry, ten of which were as executives for Thermo Fisher Scientific, Life Technologies, General Electric (GE) and Clarient Inc. 

Pages